Through the detection of 1142 clinical samples, our results found that combining the methylation levels of three markers (i.e., SEPT9, SDC2, and SFRP2) achieved good performance for predicting CRC, suggesting its potential for clinical application. The gene discussed is SFRP2; the disease is colorectal carcinoma.